NCT06969612View on ClinicalTrials.gov

A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC

PHASE1RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

May 15, 2025

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2028

Conditions
NSCLC (Advanced Non-small Cell Lung Cancer)
Interventions
DRUG

Tislelizumab

200 mg, intravenously on Day 1, every 3 weeks

DRUG

Pemetrexed

administered via IV infusion

DRUG

Cisplatin

administered via IV infusion

DRUG

Carboplatin

administered via IV infusion

DRUG

Paclitaxel

administered via IV infusion

DRUG

Albumin Paclitaxel

administered via IV infusion

DRUG

Golidocitinib

75mg, once a day orally

Trial Locations (1)

100142

RECRUITING

Peking University Cancer Hospital & Institute, Beijing

All Listed Sponsors
lead

Peking University Cancer Hospital & Institute

OTHER